We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.86B
AUM Growth
+$1.46B
Cap. Flow
+$137M
Cap. Flow %
1.74%
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$142M
2
DYN icon
Dyne Therapeutics
DYN
+$112M
3
EVH icon
Evolent Health
EVH
+$102M
4
LENZ
LENZ Therapeutics
LENZ
+$86.9M
5
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
+$71.7M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$704M
2
CBAY
Cymabay Therapeutics
CBAY
+$164M
3
ICVX
Icosavax, Inc. Common Stock
ICVX
+$94M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$93.6M
5
INBX
Inhibrx, Inc. Common Stock
INBX
+$76.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.6B
$1.53B 19.44%
10,108,400
+1,000
+0% +$143K
PCVX icon
2
Vaxcyte
PCVX
$7.68B
$560M 7.13%
8,203,754
+312,500
+4% +$21.6M
LEGN icon
3
Legend Biotech
LEGN
$3.67B
$385M 4.9%
6,861,097
+596,390
+10% +$36M
JANX icon
4
Janux Therapeutics
JANX
$921M
$345M 4.39%
9,165,652
– –
JBIO
5
Jade Biosciences
JBIO
$1.2B
$244M 3.11%
236,114
– –
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.39B
$231M 2.94%
5,330,412
– –
EVH icon
7
Evolent Health
EVH
$389M
$188M 2.39%
5,736,132
+3,187,000
+125% +$102M
NAMS icon
8
NewAmsterdam Pharma
NAMS
$3.27B
$186M 2.37%
7,864,000
– –
RXST icon
9
RxSight
RXST
$253M
$178M 2.26%
3,442,825
+38,540
+1% +$1.89M
TYRA icon
10
Tyra Biosciences
TYRA
$1.87B
$171M 2.17%
10,416,609
+3,180,155
+44% +$52.2M
EWTX icon
11
Edgewise Therapeutics
EWTX
$4.34B
$163M 2.07%
+8,909,091
New +$142M
FDMT icon
12
4D Molecular Therapeutics
FDMT
$505M
$161M 2.05%
5,051,511
+888,300
+21% +$22.7M
BIIB icon
13
Biogen
BIIB
$30.6B
$160M 2.03%
740,727
+207,835
+39% +$48.7M
PEPG icon
14
PepGen
PEPG
$120M
$157M 2%
10,689,545
+2,557,593
+31% +$30.2M
GERN icon
15
Geron
GERN
$924M
$152M 1.94%
46,202,425
– –
ETNB
16
DELISTED
89bio
ETNB
$149M 1.89%
12,766,948
+1,350,000
+12% +$14.9M
DYN icon
17
Dyne Therapeutics
DYN
$4.19B
$141M 1.79%
+4,954,779
New +$112M
APGE icon
18
Apogee Therapeutics
APGE
$10.2B
$131M 1.67%
1,977,901
– –
DAWN
19
DELISTED
Day One Biopharmaceuticals
DAWN
$129M 1.64%
7,809,852
– –
NKTX icon
20
Nkarta
NKTX
$153M
$117M 1.49%
10,805,129
+3,000,000
+38% +$31.2M
WVE icon
21
Wave Life Sciences
WVE
$1.12B
$112M 1.43%
18,202,009
– –
SPRY icon
22
ARS Pharmaceuticals
SPRY
$571M
$111M 1.41%
10,860,977
+1,401,299
+15% +$10.4M
FULC icon
23
Fulcrum Therapeutics
FULC
$247M
$110M 1.39%
11,609,704
– –
VRNA
24
DELISTED
Verona Pharma
VRNA
$102M 1.29%
6,317,990
– –
LENZ
25
LENZ Therapeutics
LENZ
$178M
$93.3M 1.19%
+4,178,823
New +$86.9M
1
2 3 4

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, RA Capital Management held 83 positions worth $7.86B, up 23% from $6.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

RA Capital Management's Q1 2024 filing shows 21 new, 18 increased, 5 reduced and 7 closed positions. Its largest new stake was Edgewise Therapeutics: 8,909,091 shares worth $163M. The largest sale was Immunogen Inc, an estimated $704M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • RA Capital Management's largest Q1 2024 buy was Edgewise Therapeutics: 8,909,091 shares worth $163M.
  • RA Capital Management added most to Evolent Health in Q1 2024, an estimated $102M increase.
  • RA Capital Management's biggest Q1 2024 reduction was Inhibrx, Inc. Common Stock, cutting an estimated $76.4M.
  • RA Capital Management fully exited Immunogen Inc in Q1 2024, selling an estimated $704M.
  • RA Capital Management's ten largest holdings make up 51% of its $7.86B portfolio in Q1 2024.
  • RA Capital Management opened 21 new positions and closed 7 in Q1 2024.
  • RA Capital Management's portfolio value rose 23% quarter-over-quarter to $7.86B.

Based on RA Capital Management's 13F filing for Q1 2024, filed 15 May 2024.